2022
DOI: 10.1186/s12913-022-08676-x
|View full text |Cite
|
Sign up to set email alerts
|

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

Abstract: Background ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount for ALL chemotherapy, but additional money needed to treat any other unexpected condition should be taken from the budget of the oncologic healthcare providers. So the purpose of our study was to estimate and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 21 publications
(30 reference statements)
0
1
0
Order By: Relevance
“…4 Remission induction is a major block of chemotherapy, and several complications are known to occur during this phase—febrile neutropenia, sepsis, bleeding, anemia, gastrointestinal disturbances, hepatic dysfunction, pancreatitis, venous thrombosis, etc. 5 Hepatic dysfunction could be due to leukemic infiltrates in the liver, nonalcoholic steatohepatitis, sepsis, hepatotropic viral infections, therapy-related toxicity seen due to asparaginase, rarely hyperinflammatory syndromes like hemophagocytic lymphohistiocytosis (HLH), and indirect hyperbilirubinemia due to underlying genetic syndromes like Gilbert's syndrome. 6 Hepatic dysfunction can contribute to morbidity by adding on to the underlying disease, delaying chemotherapy, dose modifications of chemotherapeutic agents, and rarely can cause mortality due to fulminant hepatic failure.…”
Section: Introductionmentioning
confidence: 99%
“…4 Remission induction is a major block of chemotherapy, and several complications are known to occur during this phase—febrile neutropenia, sepsis, bleeding, anemia, gastrointestinal disturbances, hepatic dysfunction, pancreatitis, venous thrombosis, etc. 5 Hepatic dysfunction could be due to leukemic infiltrates in the liver, nonalcoholic steatohepatitis, sepsis, hepatotropic viral infections, therapy-related toxicity seen due to asparaginase, rarely hyperinflammatory syndromes like hemophagocytic lymphohistiocytosis (HLH), and indirect hyperbilirubinemia due to underlying genetic syndromes like Gilbert's syndrome. 6 Hepatic dysfunction can contribute to morbidity by adding on to the underlying disease, delaying chemotherapy, dose modifications of chemotherapeutic agents, and rarely can cause mortality due to fulminant hepatic failure.…”
Section: Introductionmentioning
confidence: 99%